152 related articles for article (PubMed ID: 16686323)
1. [Therapeutic drug monitoring: A pharmacotherapeutic tool in psychiatry].
Stephan PL; Etzensberger M; Jaquenoud Sirot E
Praxis (Bern 1994); 2006 Apr; 95(17):671-8. PubMed ID: 16686323
[TBL] [Abstract][Full Text] [Related]
2. Outliers on the dose-response curve: how to minimize this problem using therapeutic drug monitoring, an underutilized tool in psychiatry.
Preskorn SH
J Psychiatr Pract; 2010 May; 16(3):177-82. PubMed ID: 20485106
[TBL] [Abstract][Full Text] [Related]
3. Is pharmacogenetic CYP2D6 testing useful?
Vetti HH; Molven A; Eliassen AK; Steen VM
Tidsskr Nor Laegeforen; 2010 Nov; 130(22):2224-8. PubMed ID: 21109842
[TBL] [Abstract][Full Text] [Related]
4. The convergence of conventional therapeutic drug monitoring and pharmacogenetic testing in personalized medicine: focus on antidepressants.
Sjöqvist F; Eliasson E
Clin Pharmacol Ther; 2007 Jun; 81(6):899-902. PubMed ID: 17392719
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and therapeutic drug monitoring of psychotropic drugs in pediatrics.
Pichini S; Papaseit E; Joya X; Vall O; Farré M; Garcia-Algar O; de laTorre R
Ther Drug Monit; 2009 Jun; 31(3):283-318. PubMed ID: 19363463
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic drug monitoring. Principles and practice.
Preskorn SH; Burke MJ; Fast GA
Psychiatr Clin North Am; 1993 Sep; 16(3):611-45. PubMed ID: 8415237
[TBL] [Abstract][Full Text] [Related]
7. Cytochromes and psychotropic drug interactions.
Bates GD; Van Woerkom AE
Br J Psychiatry; 1996 Nov; 169(5):670. PubMed ID: 8932910
[No Abstract] [Full Text] [Related]
8. The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry.
Baumann P; Hiemke C; Ulrich S; Eckermann G; Gaertner I; Gerlach M; Kuss HJ; Laux G; Müller-Oerlinghausen B; Rao ML; Riederer P; Zernig G;
Pharmacopsychiatry; 2004 Nov; 37(6):243-65. PubMed ID: 15551191
[TBL] [Abstract][Full Text] [Related]
9. Multicenter study on the clinical effectiveness, pharmacokinetics, and pharmacogenetics of mirtazapine in depression.
Jaquenoud Sirot E; Harenberg S; Vandel P; Lima CA; Perrenoud P; Kemmerling K; Zullino DF; Hilleret H; Crettol S; Jonzier-Perey M; Golay KP; Brocard M; Eap CB; Baumann P
J Clin Psychopharmacol; 2012 Oct; 32(5):622-9. PubMed ID: 22926595
[TBL] [Abstract][Full Text] [Related]
10. Individual clearance and therapeutic drug monitoring of quetiapine in clinical practice.
Wittmann M; Hausner H; Köstlbacher A; Hajak G; Haen E
Neuro Endocrinol Lett; 2010; 31(2):203-7. PubMed ID: 20424588
[TBL] [Abstract][Full Text] [Related]
11. Citalopram: an interaction study with clomipramine in a patient heterozygous for CYP2D6 genotype.
Haffen E; Vandel P; Broly F; Vandel S; Sechter D; Bizouard P; Bechtel PR
Pharmacopsychiatry; 1999 Nov; 32(6):232-4. PubMed ID: 10599932
[TBL] [Abstract][Full Text] [Related]
12. [Therapeutic drug monitoring in child and adolescent psychiatry--practical recommendations].
Gerlach M; Rothenhöfer S; Mehler-Wex C; Fegert JM; Schulz E; Wewetzer C; Warnke A
Z Kinder Jugendpsychiatr Psychother; 2006 Jan; 34(1):5-13. PubMed ID: 16485609
[TBL] [Abstract][Full Text] [Related]
13. The combination of pharmacogenetic and pharmacokinetic analyses to optimize clomipramine dosing in major depression: a case report.
Antoniazzi S; Tatulli A; Falvella FS; Cigliobianco M; Paoli RA; Cattaneo D; Cheli S; Bernardi FF; Clementi E; Altamura CA
J Clin Pharm Ther; 2017 Feb; 42(1):119-121. PubMed ID: 27800629
[TBL] [Abstract][Full Text] [Related]
14. A practitioner's guide to use of psychotropic medication in liquid form.
Geller JL; Gaulin BD; Barreira PJ
Hosp Community Psychiatry; 1992 Oct; 43(10):969-71. PubMed ID: 1356908
[No Abstract] [Full Text] [Related]
15. Pharmacogenetics of debrisoquine and its use as a marker for CYP2D6 hydroxylation capacity.
Llerena A; Dorado P; Peñas-Lledó EM
Pharmacogenomics; 2009 Jan; 10(1):17-28. PubMed ID: 19102711
[TBL] [Abstract][Full Text] [Related]
16. The impact of cytochrome P450-2D6 genotype on the use and interpretation of therapeutic drug monitoring in long-stay patients treated with antidepressant and antipsychotic drugs in daily psychiatric practice.
Mulder H; Herder A; Wilmink FW; Tamminga WJ; Belitser SV; Egberts AC
Pharmacoepidemiol Drug Saf; 2006 Feb; 15(2):107-14. PubMed ID: 16294366
[TBL] [Abstract][Full Text] [Related]
17. CYP2D6 genotyping for psychiatric patients treated with risperidone: considerations for cost-effectiveness studies.
Rodríguez-Antona C; Gurwitz D; de Leon J; Llerena A; Kirchheiner J; de Mesa EG; Ibarreta D
Pharmacogenomics; 2009 Apr; 10(4):685-99. PubMed ID: 19374522
[TBL] [Abstract][Full Text] [Related]
18. Adverse drug reactions following nonresponse in a depressed patient with CYP2D6 deficiency and low CYP 3A4/5 activity.
Stephan PL; Jaquenoud Sirot E; Mueller B; Eap CB; Baumann P
Pharmacopsychiatry; 2006 Jul; 39(4):150-2. PubMed ID: 16871470
[TBL] [Abstract][Full Text] [Related]
19. [Clinical significance of pharmacogenetics in psychiatry].
Skrętkowicz J; Barańska M; Rychlik-Sych M
Wiad Lek; 2013; 66(2 Pt 2):185-91. PubMed ID: 25775815
[TBL] [Abstract][Full Text] [Related]
20. Pharmacogenetic study on risperidone long-acting injection: influence of cytochrome P450 2D6 and pregnane X receptor on risperidone exposure and drug-induced side-effects.
Choong E; Polari A; Kamdem RH; Gervasoni N; Spisla C; Jaquenoud Sirot E; Bickel GG; Bondolfi G; Conus P; Eap CB
J Clin Psychopharmacol; 2013 Jun; 33(3):289-98. PubMed ID: 23609392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
